Physician profile
Vladimir Troche
NPI 1518959477
$477.19
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $32.98 · 2021: $38.96 · 2022: $193 · 2023: $24.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $139.02 | 2022 | |
| Merck Sharp & Dohme LLC | $129.24 | 2019 | |
| Ferring Pharmaceuticals INC. | $71.48 | 2019-2020 | |
| Organon LLC | $58.27 | 2022-2023 | Follistim Aq |
| Hologic Sales and Service, LLC | $40.22 | 2019-2022 | |
| Emd Serono, INC. | $38.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Troche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.